These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30945389)

  • 1. Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer.
    Li K; Liu W; Zhao Q; Wu C; Fan C; Lai H; Li S
    Phytother Res; 2019 Jun; 33(6):1658-1669. PubMed ID: 30945389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanshinone IIA potentiates the chemotherapeutic effect of doxorubicin against breast cancer cells and attenuates the cardiotoxicity of doxorubicin by regulating ERK1/2 pathway.
    Li S; FeiyuTeng ; Zhang J; Zhang P; Li M; Wang X; Li K
    J Biochem Mol Toxicol; 2024 Oct; 38(10):e23851. PubMed ID: 39267350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters.
    Li K; Lai H
    Biomed Pharmacother; 2017 Dec; 96():371-377. PubMed ID: 29028589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it.
    Li S; Yuan S; Zhao Q; Wang B; Wang X; Li K
    Biomed Pharmacother; 2018 Apr; 100():441-447. PubMed ID: 29475141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
    Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
    Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone.
    Sun G; Sun K; Sun J
    Drug Deliv; 2021 Dec; 28(1):1132-1140. PubMed ID: 34121558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tanshinone IIA inhibits cardiomyocyte apoptosis and rescues cardiac function during doxorubicin-induced cardiotoxicity by activating the DAXX/MEK/ERK1/2 pathway.
    Xu L; He D; Wu Y; Shen L; Wang Y; Xu Y
    Phytomedicine; 2022 Dec; 107():154471. PubMed ID: 36182795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
    Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
    Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of SIRT3 by Tanshinone IIA ameliorates renal fibrosis by suppressing the TGF-β/TSP-1 pathway and attenuating oxidative stress.
    Fan Y; Kang S; Shao T; Xu L; Chen J
    Cell Signal; 2024 Oct; 122():111348. PubMed ID: 39153586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting β-catenin nuclear translocation.
    Li S; Wu C; Fan C; Zhang P; Yu G; Li K
    J Biochem Mol Toxicol; 2021 Jan; 35(1):e22620. PubMed ID: 32886829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
    Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
    Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quercetin Increase the Chemosensitivity of Breast Cancer Cells to Doxorubicin Via PTEN/Akt Pathway.
    Li SZ; Qiao SF; Zhang JH; Li K
    Anticancer Agents Med Chem; 2015; 15(9):1185-9. PubMed ID: 25612678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.
    Wang X; Teng Z; Wang H; Wang C; Liu Y; Tang Y; Wu J; Sun J; Wang H; Wang J; Lu G
    Int J Clin Exp Pathol; 2014; 7(4):1337-47. PubMed ID: 24817930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal
    He S; Wang M; Zhang Y; Luo J; Zhang Y
    Contrast Media Mol Imaging; 2019; 2019():2374565. PubMed ID: 31281233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saikosaponin D potentiates the antineoplastic effects of doxorubicin in drug-resistant breast cancer through perturbing NQO1-mediated intracellular redox balance.
    Luo F; Yang J; Yang X; Mi J; Ye T; Li G; Xie Y
    Phytomedicine; 2024 Oct; 133():155945. PubMed ID: 39146878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
    Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
    J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
    Zeng X; Zhang H; Oh A; Zhang Y; Yee D
    Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.